In a randomized, double-blind phase 3 trial, the anti-α4β7 integrin monoclonal antibody vedolizumab plus standard prophylaxis was superior to placebo plus prophylaxis for prevention of lower gastrointestinal acute graft-versus-host disease in patients following allogeneic hematopoietic stem cell transplantation.
- Yi-Bin Chen
- Mohamad Mohty
- Yngvar Fløisand
